These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 23074314)

  • 1. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
    Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
    Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
    Yang H; Zhang C; Zhou Q; Wang Y; Chen L
    PLoS One; 2015; 10(1):e0116769. PubMed ID: 25575030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
    Mah GT; Mabasa VH; Chow I; Ensom MH
    Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is extended or continuous infusion of carbapenems the obvious solution to improve clinical outcomes and reduce mortality?
    Frippiat F; Vercheval C; Lambermont B; Damas P
    Clin Infect Dis; 2013 Jul; 57(2):324-5. PubMed ID: 23547169
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
    McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
    Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP; Lomaestro B; Drusano GL
    Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis.
    Yang H; Cui X; Ma Z; Liu L
    J Pharm Pharm Sci; 2016; 19(2):274-89. PubMed ID: 27518175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
    D'Agostino C; Rhodes NJ; Skoglund E; Roberts JA; Scheetz MH
    J Infect Chemother; 2015 Oct; 21(10):742-6. PubMed ID: 26143049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of piperacillin-tazobactam.
    Hayashi Y; Roberts JA; Paterson DL; Lipman J
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
    Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and evidence for extended infusion of piperacillin-tazobactam.
    Kaufman SE; Donnell RW; Hickey WS
    Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
    Lee GC; Liou H; Yee R; Quan CF; Neldner K
    Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.